MOSPD2 and epilepsy: As it has been demonstrated silencing or neutralizing MOSPD2 not only reduced the proportion of inflammatory monocytes in the blood significantly but also inhibited monocyte migrating into CNS [108], MOSPD2 may be a potential target for the treatment of epilepsy.